All News Nyrada Inc.

Equities

Delayed Australian S.E. Other stock markets 05:31:43 25/06/2024 BST			5-day change	1st Jan Change
0.053 ^AUD	-5.36%		-10.17%	+140.91%

04-30	Nyrada's NYR-BI03 Being Studied For Potential in Traumatic Brain Injury	MT
04-18	Transcript : Nyrada Inc., Q3 2024 Earnings Call, Apr 18, 2024

Nyrada's NYR-BI03 Being Studied For Potential in Traumatic Brain Injury	04-30	MT
Transcript : Nyrada Inc., Q3 2024 Earnings Call, Apr 18, 2024	04-18
Transcript : Nyrada Inc. - Special Call	04-10
Nyrada Begins Animal Testing on NYR-BI03 Brain Injury Program	04-10	MT
Nyrada Begins Good Laboratory Practice Preclinical Study for Brain Injury Drug Candidate	03-28	MT
Nyrada Raises AU$1.8 Million via Placement	03-06	MT
Nyrada Inc. Reports Earnings Results for the Half Year Ended December 31, 2023	02-20	CI
Nyrada Secures AU$3.5 Million R&D Tax Rebate for Fiscal Year 2023; Shares Surge 30%	12-08	MT
Nyrada Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	28/08/23	CI
Australian Shares Flat as June Unemployment Rate Remains at 3.5%	20/07/23	MT
Nyrada Halves Director Fees; Shares Jump 37%	20/07/23	MT
Nyrada Opts to Advance NYR-BI03 Brain Injury Drug Candidate	12/06/23	MT
Nyrada Completes Preclinical Studies on Cholesterol Lowering Medication	26/05/23	MT
Nyrada Completes Preclinical Dose Formulation for Cholesterol Lowering Medication	11/04/23	MT
Nyrada Inc. Reports Earnings Results for the Half Year Ended December 31, 2022	23/02/23	CI
Nyrada Extends R&D Deal for Brain Injury Drug Candidate	18/01/23	MT
Nyrada Inc. Announces Collaboration with Walter Reed and UNSW Extended to 2025	17/01/23	CI
Nyrada Advances Preclinical Studies for Brain Injury Drug Candidate	11/01/23	MT
Nyrada Inc. Provides Update on the Progress of Its Brain Injury Program	10/01/23	CI
Nyrada Receives $804,600 R&D Tax Refund; Shares fall 11%	18/11/22	MT

No results for this search